



26-
1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: KATO18

In re Application of:)	Confirmation No.: 8012
Ikunoshin KATO et al)	
)	Art Unit:
)	
Appln. No.: 09/937,375)	Examiner:
)	
Filed: September 24, 2001)	Washington, D.C.
)	
For: GENE THERAPEUTICS)	August 17, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

(Check one of the boxes "i" and "ii" below:)

[X] i. Counsel certifies that, upon information and belief, each item of information listed herein was either

[X] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. Other information being provided for the examiner's consideration follows:

*Official Action dated June 18, 2004 issued in Taiwan Patent
Application No. 089104822*


5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of

the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.


Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Jay M. Finkelstein
Reg. No. 21,082

JMF:ses
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\A\Aoyb\Kato18\PTO\ids.fee13AU2004.doc



Substitute for form PTO/SB/C8a INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Sheet 1 of 1		Application Number	09/937,375
		Filing Date	September 24, 2001
		First Named Inventor	Ikunoshin KATO
		Group Art Unit	_____
		Examiner Name	_____
		Attorney Docket Number	KATO18

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AP	CONNALLY E. EAVES CJ, HUMPHRIES RK, "Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential" Blood, vol. 91, No. 9, May 1, 1998: pp 3487-3493	
	AQ	KIEM HP et al, "Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment GH296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor" Blood, September 15, 1998; Vol. 92 No. 6, pp.1878-1886	
	AR	MASON CA et al "Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation" Nat. Med vol 5, No.2, February 1999: pp. 176-182	
	AS	MORITZ T et al "Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments" Blood, August 1, 1996; vol 88, No.3: 855-862	

Examiner Signature	Date Considered
--------------------	-----------------

The PRO did not receive the following listed items(s) Received AR-2 Page AR-1 Page AS 1 Page

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.